Section Arrow
Quote
APUS.NYSE-M
- Apimeds Pharmaceuticals US Inc.
Quotes are at least 15-min delayed:2025/05/10 11:55 EDT
Last
 2.2
-1.8 (-45.00%)
Day High 
4 
Prev. Close
4 
1-M High
-- 
Volume 
1.68M 
Bid
2.15
Ask
2.31
Day Low
2.04 
Open
4 
1-M Low
-- 
Market Cap 
-- 
Currency USD 
P/E -- 
%Yield -- 
10-SMA -- 
20-SMA -- 
50-SMA -- 
52-W High 4 
52-W Low 2.04 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-0.11/--
Enterprise Value
--
Balance Sheet
Book Value Per Share
N/A
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
SHPHShuttle Pharmaceuticals Holdings Inc0.2325-0.0375-13.89%-- 
PTPIPetros Pharmaceuticals Inc0.1201-0.0053-4.23%-- 
VTRSViatris8.77-0.32-3.52%227.2PE
TEVATeva Pharmaceutical Industries Limited16.93-1.14-6.31%-- 
IXHLIncannex Healthcare0.1135+0.0009+0.80%-- 
Quotes are at least 15-min delayed：2025/05/10 11:55 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Apimeds Pharmaceuticals Us Inc is a clinical-stage company. It is engaged in a pharmaceutical business that provides the biological drug Apitox to clients in the biological drug commercial transaction area. It are a clinical stage biopharmaceutical company in the process of developing Apitox, an intradermally administered bee venom-based toxin. Company focus is on developing therapies that address inflammation and pain management symptoms associated with knee OA and, to a lesser extent, MS. Apitox is currently marketed and sold by Apimeds Inc. in South Korea as Apitoxin for the treatment of OA.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.